Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels - Full Text View

Purpose

The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical location and timing of administration of TIG and TT. Pharmacokinetic profile of antibody titer including the duration of adequate titer protection provided by TIG and TT given in combination will be assessed using a standardized administration regimen and standardized antibody assay procedure. This study may provide evidence for the recommendations of the World Health Organisation (WHO) whereby dual coverage with both a vaccine and tetanus hyperimmune would ideally provide the best coverage for anyone with the potential of developing tetanus.

Condition	Intervention	Phase
Tetanus	Drug: Tetanus Immune Globulin (Human) Biological: Diphtheria-Tetanus Toxoids Adsorbed	Phase IV

MedlinePlus related topics:

Tetanus

ChemIDplus related topics:

Tetanus Vaccine Immunoglobulins Globulin, Immune

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study

Official Title:	Pharmacokinetics Of Active And Passive Tetanus Immunization Given Concurrently In Subjects With No Known Primary Immunization History Or In Subjects With Tetanus Antibody Levels Below Protective Levels

Further study details as provided by Talecris Biotherapeutics:

Primary Outcome Measures:

Antibody titer serum level at each time point [ Time Frame: 40 days ]
Cmax [ Time Frame: 40 days ]
Tmax [ Time Frame: 40 days ]

Enrollment:	6
Study Start Date:	March 2007
Study Completion Date:	September 2007

Arms	Assigned Interventions
Entered study: Experimental	Drug: Tetanus Immune Globulin (Human) Biological: Diphtheria-Tetanus Toxoids Adsorbed

Detailed Description:

This is a prospective, open-label, single-center trial including a single group of subjects with no known primary immunization history with TT or >10 years have passed since the last dose of tetanus containing vaccine was received. The study will enroll six subjects who will receive both dT and TIG concurrently on Day 1.

All dosed subjects will be followed for 40 days during which Day 1, 2, 3, 4, 5, 7, 14, 21, 30 and 40 time levels of tetanus antibodies will be measured in order to determine the serum level vs. time curve, Cmax, Tmax, and duration of protective antibody levels.

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age between 18 and 90 years.
Signed a written informed consent prior to initiation of any study-related procedures.
No known primary immunization history with TT/dT or >10 years have passed since the last dose of tetanus containing vaccine was received. Subjects with unknown or uncertain previous vaccination histories are considered to have no previous tetanus and toxoid doses. Subjects who have had military service since 1941 will be considered to have had 1 dose of tetanus vaccine.
Subjects must have documented tetanus antibody levels that are non-protective levels (< 0.15 IU/ml).
Subjects must be free of any presenting wound or wound infection

Exclusion Criteria:

History or suspicion of significant allergic reaction to intravenous immune globulin, and or blood products
A history of selective IgA deficiency (serum level <5.0 mg/dL) and known antibodies to IgA
Congestive heart failure (New York Association stage greater than Class II)
Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
Women of child bearing potential who do not practice adequate contraception (i.e. chemical or mechanical methods) and pregnant or lactating females
Subjects who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
TIG therapy within the previous six months
Investigational drug therapy within the previous three months
History of Thromboembolism

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00437671

Locations


United States, New York
	Long Island Jewish Medical Center
	New Hyde Park, New York, United States, 11040

Sponsors and Collaborators

Talecris Biotherapeutics

Investigators


Principal Investigator:	Kumar Alagappan, MD	Long Island Jewish Medical Center

More Information

FDA approved labeling information This link exits the ClinicalTrials.gov site

Study Results This link exits the ClinicalTrials.gov site

Study ID Numbers:	060002
First Received:	February 20, 2007
Last Updated:	March 25, 2008
ClinicalTrials.gov Identifier:	NCT00437671
Health Authority:	United States: Institutional Review Board